All Pharmaceutical industry articles
View all stories with this category.
-
BusinessCoronavirus variants stymie success of monoclonal antibodies
Lab-made antibodies can treat and protect people from Covid-19 but are more likely to succeed when administered as a cocktail
-
Opinion
A rough guide to pharma partnership deals
Coronavirus vaccines are driving unusual collaborations with a range of benefits
-
Webinar
Gaining an edge through smarter experimentation
Join us on March 16 to learn how to double your R&D capacity and get more products to market in less time – and at a lower cost
-
Business
Biggest venture yet of any pharma company into cannabis
Jazz Pharmaceuticals buys cannabinoid therapeutic firm for $7.2 billion, inheriting first plant-derived cannabinoid medicine ever approved by FDA
-
Business
Covid vaccination efforts bolstered by trial results from J&J and Novavax
A miserable January ended with positive news on the vaccine front but new variants added complications
-
Opinion
Ruling out the rule of five
Simple calculations for clinical trial success failed to find a winning formula
-
Business
Can chemistry thaw the vaccine cold chain?
Covid-19 has highlighted the challenges of storing vaccines at their proper temperature. Angeli Mehta explores how scientists are trying to protect vaccines from heat degradation
-
Business
Vaccine approvals offer hope as global Covid cases surge
A handful of vaccines are now approved and the first doses are being given to patients, with trials for many more candidates nearing completion
-
Business
Industry expects problems ahead after initial relief over Brexit deal
Uncertainty still looms over regulation and logistics
-
Webinar
Good practices in data analytics
Join us to learn how the University of Limerick develops skills and knowledge of data analytics via their Pharmaceutical Manufacturing Technology Centre (PMTC)
-
Business
Pharmaceuticals roundup 2020
Alongside the race for Covid-19 treatments and vaccines, the industry has maintained momentum
-
Business
AstraZeneca to buy rare disease drugmaker Alexion in $39bn deal
Transaction would be the largest in AstraZeneca’s history
-
Business
Pfizer–BioNTech vaccine gains emergency approvals in US, Canada and beyond
UK begins vaccinating vulnerable populations after early authorisation
-
Opinion
Stirring in my sleep
Cut off from the lab after 40 years, Derek Lowe returns to the bench in his dreams
-
Business
UK grants Pfizer–BioNTech Covid-19 vaccine emergency approval
Regulators around the world working towards accelerated decisions on vaccine data
-
Business
Brexit may put some chemicals out of GB’s Reach
Industry fears divergence of UK and EU regulations could spell disaster for trade
-
-
Business
Oxford–AstraZeneca vaccine joins others with promising interim data
Cheap and fridge-stable candidate at least 60% and up to 90% effective at preventing disease
-
Business
Regulatory panel unconvinced by Alzheimer’s antibody evidence
US FDA advisors vote against approving Biogen’s aducanumab on the basis of incomplete data analysis
-
Business
Moderna and Pfizer’s Covid-19 vaccines add more encouraging data
Pfizer–BioNTech reach safety threshold for emergency authorisation, while Moderna’s data peek suggests 95% efficacy
